(6Z)-5-imino-6-[(4-oxo-4H-chromen-3-yl)methylidene]-5,6-dihydro-7H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-7-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: (6Z)-5-imino-6-[(4-oxo-4H-chromen-3-yl)methylidene]-5,6-dihydro-7H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-7-one
• 英文别名: (6Z)-5-imino-6-[(4-oxochromen-3-yl)methylidene]-[1,3,4]thiadiazolo[3,2-a]pyrimidin-7-one
• 化学式: C₁₅H₈N₄O₃S
• 分子量: 324.3
• InChiKey: FJAJNDQHDCPAKD-YRYWFDQNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  121
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES
  申请人：RICCIARDI Robert P.

  公开号：US20100035887A1

  公开（公告）日：2010-02-11

  This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula I, formula XXI, formula XXXII, or formula XLI which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and/or its interaction with its processivity factor. Formula I, formula XXI, formula XXXII, or formula XLI can be utilized to treat humans and animals suffering from a poxvirus infection. Pharmaceutical compositions for treating poxvirus infected subjects are also provided.

  本发明提供了一种通过将痘病毒与具有公式I、公式XXI、公式XXXII或公式XLI的化合物接触来抑制痘病毒复制的方法，进而减少、抑制或消除痘病毒DNA聚合酶活性和/或其与其过程性因子的相互作用。公式I、公式XXI、公式XXXII或公式XLI可用于治疗患有痘病毒感染的人类和动物。还提供了用于治疗痘病毒感染受试者的药物组合物。
• US8278342B2
  申请人：——

  公开号：US8278342B2

  公开（公告）日：2012-10-02
• US8524719B2
  申请人：——

  公开号：US8524719B2

  公开（公告）日：2013-09-03
• US9211296B2
  申请人：——

  公开号：US9211296B2

  公开（公告）日：2015-12-15
• [EN] THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES<br/>[FR] COMPOSÉS THÉRAPEUTIQUES POUR UN BLOCAGE DE LA SYNTHÈSE D'ADN DE POXVIRUS
  申请人：UNIV PENNSYLVANIA

  公开号：WO2009008906A2

  公开（公告）日：2009-01-15

  This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula I, formula XXI, formula XXXII, or formula XLI which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and/or its interaction with its processivity factor. Formula I, formula XXI, formula XXXII, or formula XLI can be utilized to treat humans and animals suffering from a poxvirus infection. Pharmaceutical compositions for treating poxvirus infected subjects are also provided.